Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08929_nanopub.RAeGP9WLmxphaz5LsXHMjVq93rd51R8HPpYYJTGIAeaKY#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB08929 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08929 label "MK-8931 [drugbank:DB08929]" assertion.
- drugbank:DB08929 seeAlso DB08929 assertion.
- drugbank:DB08929 identifier "drugbank:DB08929" assertion.
- drugbank:DB08929 description "MK-8931 is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. In July 2013, Merck announced positive results for Phase Ib trials of MK-8931. In the study, administration of MK-8931 at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of 57, 79 and 84 percent, respectively. MK-8931 is currently in Phase II/III trials." assertion.
- drugbank:DB08929 title "MK-8931" assertion.
- drugbank:DB08929 bio2rdf_vocabulary:identifier "DB08929" assertion.
- drugbank:DB08929 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08929 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08929" assertion.
- drugbank:DB08929 bio2rdf_vocabulary:x-identifiers.org DB08929 assertion.
- drugbank:DB08929 drugbank_vocabulary:drugbank-id "DB08929" assertion.
- drugbank:DB08929 drugbank_vocabulary:x-cas cas: assertion.